摘要
目的研究门冬胰岛素联合阿托伐他汀对糖尿病肾病患者的疗效及对氧化应激反应的影响。方法选择2018年1月~2019年12月收治的63例糖尿病肾病患者,随机分为两组。对照组单用门冬胰岛素,观察组采用门冬胰岛素联合阿托伐他汀。结果观察组的有效率为93.55%,明显高于对照组的71.87%(P<0.05);治疗后,两组的血清GSH-Px和SOD水平均明显升高(P<0.05),血清MDA水平明显下降(P<0.05),且观察组的变化幅度明显大于对照组(P<0.05);治疗后,两组的血清NO和FMD水平明显升高(P<0.05),血清vWF、3-NT和PAI-1水平明显降低(P<0.05),且观察组的变化幅度明显大于对照组(P<0.05);治疗后,两组的血清TGF-β_(1)和TIMP-1水平明显降低(P<0.05),且观察组的变化幅度明显大于对照组(P<0.05)。结论门冬胰岛素联合阿托伐他汀能提升糖尿病肾病患者机体的抗氧化能力,减轻氧化应激反应和肾脏纤维化程度,保护血管功能。
Objective To investigate the effect of insulinaspart combined with atorvastatin on diabetic nephropathy and oxidative stress.Methods Selected 63 cases of patients with diabetic nephropathy who were treated in our hospital from January 2018 to December 2019,divided into two groups randomly.The control group was treated with insulin aspart only,while the observation group was treated with insulin aspart combined with atorvastatin.Results The effective rate of the observation group(93.55%)was significantly higher than control group(71.87%,P<0.05).After treatment,the serum GSH-Px and SOD levels of the two groups were significantly increased(P<0.05),and the serum MDA level was significantly decreased(P<0.05),and the the changes in the observation group were more obvious than those in the control group(P<0.05).After treatment,the levels of serum NO and FMD were significantly increased(P<0.05),and the levels of serum vWF,3-NT and PAI-1 in the two groups were significantly decreased(P<0.05),and the the changes in the observation group were more obvious than those in the control group(P<0.05),After treatment,the levels of serum TGF-β_(1) and TIMP-1 in the two groups were significantly decreased(P<0.05),the the changes in the observation group were more obvious than those in the control group(P<0.05).Conclusion Insulin aspart combined with atorvastatin can improve the antioxidant capacity of patients with diabetic nephropathy,reduce oxidative stress reaction and renal fibrosis,and protect vascular function.
作者
田盼丽
尚涛
TIAN Pan-li;SHANG Tao(Endocrinology Department,The People’s Hospital of Ningxia,Yinchuan 750000,China;不详)
出处
《中国处方药》
2022年第1期116-119,共4页
Journal of China Prescription Drug
关键词
门冬胰岛素
阿托伐他汀
糖尿病肾病
氧化应激反应
肾纤维化
血管功能
Insulin aspart
Atorvastatin
Diabetic nephropathy
Oxidative stress response
Renal fibrosis
Vascular function